Levi & Korsinsky Alerts Investors Regarding Regeneron Lawsuit Participation Deadline

Important Update for Regeneron Investors

Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, has issued an important reminder for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who have experienced financial losses due to alleged securities fraud are urged to take note that the deadline to petition to be appointed as the lead plaintiff in a class action lawsuit is March 10, 2025.

Background of the Lawsuit

The class action lawsuit pertains to a series of alleged fraudulent activities involving Regeneron that occurred between November 2, 2023, and October 30, 2024. During this period, Regeneron allegedly made misleading representations regarding the pricing strategies of its renowned product, Eylea, which treat chronic eye diseases.

The lawsuit claims that the company failed to disclose critical information regarding its pricing structures and dealings with distributors. Specifically, it is alleged that Regeneron paid credit card processing fees to distributors under certain conditions, which were designed to manipulate the selling prices of Eylea.

These manipulative tactics purportedly allowed Regeneron to offer lower prices for its products when purchased with credit cards, thus misleading investors about the actual sales performance of Eylea.

Allegations of Misleading Practices

Among the key accusations in the lawsuit are claims that Regeneron:
1. Concealed its payment of credit card fees which effectively acted as price concessions, leading to misrepresentation of sales figures.
2. Misled investors about Eylea's performance by failing to report the payments accurately, resulting in inflated revenue figures.
3. Violated the False Claims Act by overstating Average Sales Prices (ASP) reported to federal agencies.

These assertions reflect a significant breach of trust between Regeneron and its investors and paint a concerning picture of corporate integrity. Investors who believe they have suffered due to this misconduct are encouraged to reach out to Levi & Korsinsky for assistance in potentially recovering their losses.

What Investors Should Do

This legal action presents a critical opportunity for affected shareholders. If you suffered financial losses in Regeneron during the pertinent timeframe, now is the time to take action. Should you wish to be considered as a lead plaintiff, the deadline to act is March 10, 2025. However, it is important to note that participation in the case does not predetermine one’s capacity to share in any potential recovery.

Regeneron investors are reminded that the legal fees and costs associated with this class action may be covered at no upfront cost to the plaintiffs, allowing you to pursue this matter without financial risk.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, the team at Levi & Korsinsky has successfully secured substantial recoveries for wronged shareholders. Their expertise and track record of handling complex cases make them a trusted advocate for investors. With a dedicated staff exceeding 70 employees, they are well-equipped to serve clients in this critical period.

Levi & Korsinsky has consistently ranked amongst the top firms for securities class actions, reinforcing their commitment to shareholder rights and justice.
Contact details for follow-up inquiries are provided below:

Conclusion

As the situation develops, it is essential for Regeneron investors to stay informed and understand their rights. March 10, 2025, marks a crucial date for action. This class action lawsuit could represent an important step toward accountability and recovery for shareholders impacted by Regeneron’s alleged misdeeds.